Ben Adams

6 days ago | fiercebiotech.com | Ben Adams

Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China biopharma Minghui Pharmaceutical. The pact centers on MHB088C, a B7-H3-targeted antibody-drug conjugate that is in trials for solid tumors, including in subgroups of patients with small cell lung cancer and metastatic castration-resistant prostate cancer.

1 week ago | fiercebiotech.com | Ben Adams

RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after discontinuing its lead drug program and just over a year after a similar cost-cutting drive. These latest cuts, which affect nine roles, are set to be “substantially complete by the end of the second quarter of 2025,” the nanocap biotech said in its financial results Thursday morning.

1 week ago | fiercepharma.com | Ben Adams

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump administration. This time it’s Gilead coming to the table with a fresh $11 billion in hand to spend across its manufacturing and research canters in the U.S.Gilead broke down the new spending routes in a Wednesday release.

1 week ago | fiercebiotech.com | Ben Adams

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing its first drug asset from the deal. Lilly will pay up to $415 million in an unspecified combination of upfront, discovery milestones and royalties for ATLX-1282, Alchemab's first-in-class preclinical program for amyotrophic lateral sclerosis (ALS), as well as for “other neurodegenerative conditions,” according to a Tuesday morning release.

1 week ago | fiercebiotech.com | Ben Adams

Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for DMD was revealed as the first drug expected to face an FDA advisory committee under the new agency’s commissioner, Marty Makary, M.D. Capricor’s previously announced PDUFA date of August 31 remains, but the biotech said in a release Monday that the FDA is also now asking for an advisory committee (adcomm) to discuss the data for its Duchenne muscular dystrophy (DMD)...